Development of controlled-release cisplatin dry powders for inhalation against lung cancers

Vincent Levet, Rémi Rosière, Romain Merlos, Luca Fusaro, Gilles Berger, Karim Amighi, Nathalie Wauthoz

Résultats de recherche: Contribution à un journal/une revueArticle

Résumé

The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0% w/w exhibited high fine particle fractions ranging from 37.3% to 51.5% of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24 h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities.

langue originaleAnglais
Pages (de - à)209-220
Nombre de pages12
journalInternational Journal of Pharmaceutics
Volume515
Numéro de publication1-2
Les DOIs
étatPublié - 30 déc. 2016

Empreinte digitale

Powders
Inhalation
Cisplatin
Lung Neoplasms
Lipids
Excipients
Adjuvant Chemotherapy
Platinum
Particle Size
Spectrum Analysis
Triglycerides
Magnetic Resonance Spectroscopy
Pressure
Drug Therapy
Lung
Therapeutics
Pharmaceutical Preparations

Citer ceci

Levet, Vincent ; Rosière, Rémi ; Merlos, Romain ; Fusaro, Luca ; Berger, Gilles ; Amighi, Karim ; Wauthoz, Nathalie. / Development of controlled-release cisplatin dry powders for inhalation against lung cancers. Dans: International Journal of Pharmaceutics. 2016 ; Vol 515, Numéro 1-2. p. 209-220.
@article{8bbc8d9d0e1848dabdb3e9aa6420ff02,
title = "Development of controlled-release cisplatin dry powders for inhalation against lung cancers",
abstract = "The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0{\%} w/w exhibited high fine particle fractions ranging from 37.3{\%} to 51.5{\%} of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24 h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities.",
keywords = "Cisplatin, Controlled-release, Dry powder inhaler, Lung cancer chemotherapy, Pulmonary delivery, Solid lipid microparticles",
author = "Vincent Levet and R{\'e}mi Rosi{\`e}re and Romain Merlos and Luca Fusaro and Gilles Berger and Karim Amighi and Nathalie Wauthoz",
year = "2016",
month = "12",
day = "30",
doi = "10.1016/j.ijpharm.2016.10.019",
language = "English",
volume = "515",
pages = "209--220",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

Development of controlled-release cisplatin dry powders for inhalation against lung cancers. / Levet, Vincent; Rosière, Rémi; Merlos, Romain; Fusaro, Luca; Berger, Gilles; Amighi, Karim; Wauthoz, Nathalie.

Dans: International Journal of Pharmaceutics, Vol 515, Numéro 1-2, 30.12.2016, p. 209-220.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - Development of controlled-release cisplatin dry powders for inhalation against lung cancers

AU - Levet, Vincent

AU - Rosière, Rémi

AU - Merlos, Romain

AU - Fusaro, Luca

AU - Berger, Gilles

AU - Amighi, Karim

AU - Wauthoz, Nathalie

PY - 2016/12/30

Y1 - 2016/12/30

N2 - The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0% w/w exhibited high fine particle fractions ranging from 37.3% to 51.5% of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24 h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities.

AB - The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0% w/w exhibited high fine particle fractions ranging from 37.3% to 51.5% of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24 h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities.

KW - Cisplatin

KW - Controlled-release

KW - Dry powder inhaler

KW - Lung cancer chemotherapy

KW - Pulmonary delivery

KW - Solid lipid microparticles

UR - http://www.scopus.com/inward/record.url?scp=84992521805&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2016.10.019

DO - 10.1016/j.ijpharm.2016.10.019

M3 - Article

VL - 515

SP - 209

EP - 220

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -